Tubastatin A hydrochloride

Pricing Availability   Qty
Description: Potent HDAC6 inhibitor
Chemical Name: N-Hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide hydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations (1)
Reviews
Literature (4)

Biological Activity for Tubastatin A hydrochloride

Tubastatin A hydrochloride is a potent HDAC6 inhibitor (IC50 = 0.015 μM). Exhibits some selectively for HDAC6 over HDAC8 and 1 (IC50 values are 0.854 and 16.4 μM, respectively). Induces elevated levels of α-tubulin and protects against glutathione-induced oxidative stress in primary neuronal cell culture. Reverses the axonal loss in peripheral neurons in a mouse model of Charcot-Marie-Tooth disease.

Technical Data for Tubastatin A hydrochloride

M. Wt 371.86
Formula C20H21N3O2.HCl
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1310693-92-5
PubChem ID 57336514
InChI Key LJTSJTWIMOGKRJ-UHFFFAOYSA-N
Smiles CN1CCC2=C(C3=CC=CC=C3N2CC4=CC=C(C(NO)=O)C=C4)C1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Tubastatin A hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 3.72 10 with gentle warming

Preparing Stock Solutions for Tubastatin A hydrochloride

The following data is based on the product molecular weight 371.86. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 26.89 mL 134.46 mL 268.92 mL
0.5 mM 5.38 mL 26.89 mL 53.78 mL
1 mM 2.69 mL 13.45 mL 26.89 mL
5 mM 0.54 mL 2.69 mL 5.38 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for Tubastatin A hydrochloride

References for Tubastatin A hydrochloride

References are publications that support the biological activity of the product.

Butler et al (2010) Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J.Am.Chem.Soc. 132 10842

d'Ydewalle et al (2011) HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nature medicine 7 26 PMID: 21785432


If you know of a relevant reference for Tubastatin A hydrochloride, please let us know.

View Related Products by Product Action

View all Class II HDAC Inhibitors

Keywords: Tubastatin A hydrochloride, Tubastatin A hydrochloride supplier, HDAC6, potent, inhibitors, inhibits, histone, deacetylases, Class, II, HDACs, 6270, Tocris Bioscience

1 Citation for Tubastatin A hydrochloride

Citations are publications that use Tocris products. Selected citations for Tubastatin A hydrochloride include:

Steven L et al (2022) INF2-mediated actin filament reorganization confers intrinsic resilience to neuronal ischemic injury. Nat Commun 13 6037 PMID: 36229429


Do you know of a great paper that uses Tubastatin A hydrochloride from Tocris? Please let us know.

Reviews for Tubastatin A hydrochloride

There are currently no reviews for this product. Be the first to review Tubastatin A hydrochloride and earn rewards!

Have you used Tubastatin A hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.